Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226681 | 0.81 | ALOX5AP (0.32) | ALOX5APFEN1DUTCA12CA1 | |
| SCHEMBL3347385 | 0.78 | KDM4E (0.36) | — | |
| SCHEMBL22655811 | 0.76 | HTR2C (0.35) | ALOX5APFEN1DUTCA12CA1 | |
| SCHEMBL25355966 | 0.76 | ALOX5AP (0.33) | ALOX5APFEN1DUT | |
| SCHEMBL1225358 | 0.75 | DHFR (0.39) | DUTCA12CA1CA2CA9 | |
| SCHEMBL3340981 | 0.74 | LOX (0.37) | ALOX5APFEN1 | |
| SCHEMBL30524425 | 0.73 | MAPT (0.34) | DUT | |
| SCHEMBL21167031 | 0.73 | MAPT (0.34) | DUT | |
| SCHEMBL2253176 | 0.73 | GAA (0.39) | ALOX5APFEN1DUTCA12CA1 | |
| SCHEMBL20606894 | 0.72 | CDK8 (0.36) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2391604-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010072605-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160389-A1 | DIHYDROPYRIDONE AMIDESAS P2X7 MODULATORS | P2RX3, P2RX1, P2RY1 | ALOX5AP 1967/4885FEN1 4877/4885DUT 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.